Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 800 Official Publication of Indian Association of Medical Microbiologists 
  Search
 
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (259 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
 ~  References

 Article Access Statistics
    Viewed536    
    Printed17    
    Emailed0    
    PDF Downloaded175    
    Comments [Add]    

Recommend this journal

 


 
  Table of Contents  
CORRESPONDENCE
Year : 2017  |  Volume : 35  |  Issue : 3  |  Page : 436
 

Multidrug-resistant Candida auris: Need for alert among microbiologists


1 Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India
2 Department of Medical Mycology, V P Chest Institute, Chandigarh, India
3 Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Date of Web Publication12-Oct-2017

Correspondence Address:
Kamini Walia
Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmm.IJMM_17_345

Rights and Permissions



How to cite this article:
Walia K, Chowdhary A, Ohri V C, Chakrabarti A. Multidrug-resistant Candida auris: Need for alert among microbiologists. Indian J Med Microbiol 2017;35:436

How to cite this URL:
Walia K, Chowdhary A, Ohri V C, Chakrabarti A. Multidrug-resistant Candida auris: Need for alert among microbiologists. Indian J Med Microbiol [serial online] 2017 [cited 2018 Apr 25];35:436. Available from: http://www.ijmm.org/text.asp?2017/35/3/436/216631


Dear Editor,

Candida auris is recognised as a newly emerging species that was first identified in 2009 from the ear canal of a patient in Japan. C. auris soon became important cause of bloodstream infection in other parts of Asia and the last 8 years has emerged on other continents i.e., Africa, South America and in North America and Europe. The emergence of C. auris in India was noted in sporadic outbreaks and a multicentric study of candidemia among Intensive Care Units in 2011.[1],[2],[3],[4] This fungus is posing significant challenges to microbiologists and clinicians as (i) antifungal resistance is the norm rather than the exception, (ii) easily transmitted from person to person in a health-care setting and (iii) misidentification by standard biochemical identification systems primarily due to lack of C. auris in their databases and is mainly misidentified as Candida haemulonii by Vitek-2. Currently, accurate identification is through matrix-assisted laser desorption ionization time-of-flight mass spectrometry and sequencing. Universally, C. auris show high resistance to fluconazole and to lesser extent to amphotericin B and echinocandin. Falsely elevated MICs of amphotericin B and caspofungin are reported by Vitek 2.[5] Whole genome sequencing (WGS) of isolates from different countries support its simultaneous emergence worldwide rather than spread from one place to another. WGS of Indian isolates showed clonal origin suggesting nosocomial transmission. C. auris-specific infection control measures such as single room, contact precautions, hand hygiene and disinfection with an EPA-approved agent are recommended. The rampant threat by multidrug-resistant strains of C. auris had prompted CDC and Public Health England release clinical alerts, followed by the European Centres for Disease Control. Under the aegis of Antimicrobial resistance network, ICMR has recently issued an advisory note (http://www.icmr.nic.in/icmrnews/candida%20auris.pdf) on C. auris emphasising the need for active surveillance of this yeast among Indian hospitals and to assist with the identification and antifungal susceptibility of C. auris.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 ~ References Top

1.
Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, et al. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 2013;19:1670-3.  Back to cited text no. 1
[PUBMED]    
2.
Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015;41:285-95.  Back to cited text no. 2
[PUBMED]    
3.
Chowdhary A, Sharma C, Meis JF. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2017;13:e1006290.  Back to cited text no. 3
    
4.
Rudramurthy SM, Chakrabarti A, Paul RA, Sood P, Kaur H, Capoor MR, et al. Candida auris candidaemia in Indian ICUs: Analysis of risk factors. J Antimicrob Chemother 2017;72:1794-801.  Back to cited text no. 4
    
5.
Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by vitek 2, CLSI broth microdilution, and Etest Method. J Clin Microbiol 2015;53:1823-30.  Back to cited text no. 5
    




 

Top
Print this article  Email this article
 

    

2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04